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Abstract 
Financial challenges that the National Health Service (NHS), England, faces may jeopardise 
its future. This study evaluated the direct cost of using two different safety peripheral 
intravenous cannulae (SPIVC) with and without a blood control septum, including the cost of 
device and clinician time.  Observation of 103 cannulations demonstrated a 54 second (29%) 
time reduction per cannulation with the non-ported SPIVC with multi-use blood control 
septum (Introcan Safety® 3 B Braun), compared to the standard ported SPIVC (Vasofix® 
Safety B Braun) (P<0.05).  The direct cost analysis, including clinician time, demonstrated 
that the introduction of SPIVC with multi-use blood control septum could offer time 
efficiency savings equivalent to a reduction in average cannulation costs by 25%.   
Eighty two per cent of users perceived the insertion of SPIVC with multi-use blood control 
septum to be easy to use; 82% would choose to use it in clinical practice.   
 
Keywords: cannula, time savings, time efficiency, non-ported cannula, non-ported 
catheter, PIVC, peripheral cannula, peripheral intravenous cannula, cost saving, 
innovation, blood control septum. 
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1. Background 
The NHS spends over £20 billion each year on goods and services, which accounts for 
approximately 30 per cent of the operating costs of each hospital trust. The United Kingdom 
(UK) government plans to stabilise non-pay spending and it requires trusts to spend no more 
by the end of 2016 than they did in 2013 (NHS England 2013). This means that trusts need to 
find over £1.5 billion of procurement efficiencies by the end of 2016.  The Cabinet Office, 
Department of Health and NHS Business Services Authority have set a target of £2bn savings 
for NHS procurement, with the NHS Supply Chain contract aiming to deliver £150m by 
March 31 2016. Saving money on the procurement of supplies can be a straightforward 
process when the alternatives have the same specification and vary only in price. The 
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challenge arises when product (a) works in a different way to product (b). In this case the 
difference in the price on an individual component of a procedure may well not reflect the 
difference in value when considering a procedure as a whole. This gives rise to the potential 
for a false economy: “An apparent financial saving that in fact leads to greater 
expenditure:”(Oxford Dictionary 2014).   
Procurement departments are under pressure to meet their saving targets whilst being 
encouraged to engage in innovation to change the fundamentals of the NHS (NHS Business 
Service Authority 2014).  This poses difficulties for procurement to meet their savings targets 
whist demonstrating they are embracing innovative change that will bring benefits to the 
organisation.  Increasing the efficiency of frequently performed procedures can free up 
medical staff to deliver more patient-centred care (NHS England 2014). The use of PIVC is 
an essential means to administer medicines, blood and blood products, for parenteral feeding 
and is one of the most common procedures to occur in healthcare (Maki et al 2006).  In the 
UK one third of all patients admitted to the NHS will receive at least one PIVC (Boyd et al 
2011), giving an estimated 5 million patients per year (Castro-Sanchez et al 2014).  
Reduction in time to undertake peripheral IV cannulation could release clinician time to 
deliver other healthcare procedures. 
 
Of importance, intravenous catheter use is not without risk, from: phlebitis, cellulitis to sepsis 
amongst others (Curran and Reilly 2008). Whilst the overall infection rate of PIVC is low 
(0.1%), due to the high frequency of use of PIVC the risk of infection is likely 
underestimated (Maki et al 2006). In recent years injection through stopcock injection ports 
have been identified as a potential portal of entry for microorganisms. In general closed 
catheter systems, used with the appropriate disinfection, have been associated with fewer 
catheter related blood stream infections (Casey et al 2007, O’Grady et al 2011, Niel-Weise 
2006, and Soothill et al 2009).  However Esteve et al 2007 claim that closed catheter systems 
do not reduce infection rates.  Due to the similar set up of cannula top ports and injection 
ports of stopcocks, there has been an increase in the use of non-ported cannula within the UK 
over the last few years, with an estimated 22% of the NHS now using a non-ported cannula 
with a vascular access device (VAD) (unpublished market research data). There is increasing 
interest from infection control departments in hospitals, to implement non-ported cannula 
with a VAD. However, there is a scarcity of studies exploring the use of the top injection 
ports.  
 
2. The Study 
2.1. Aim 
The aim of this study was two fold: (i) to provide a time efficiency analysis comparing the 
use of a novel non-ported SPIVC with multi-use blood control septum against current 
practice and to correlate this saving to possible cost offset; (ii) to explore the clinical 
acceptance of a novel non-ported SPIVC with multi-use blood control septum amongst NHS 
staff in the UK.  
 
2.2.1. Methods: Time in Motion Study 
The time and motion study was a prospective, non-blinded, cohort, controlled single-centre, 
post market study, conducted in the Emergency Department of Nottingham Queens Medical 
Centre in Nottingham, the UK.  The main body of the study was designed to compare the 
effects of using a complete cannulation pack inclusive of cannula, compared with the current 
practice of collecting all separate components for the procedure separately. Timings in this 
study were collected; (i) after collection of all items, (ii) at arrival back at patient bed side 
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(iii) after preparation of equipment and just prior to skin cleansing, (iv) from skin cleansing 
and after connection of VAD and documentation completed. 
 
The time in motion data here consists of an analysis of stage (iv) only, comparing the use of a 
non-ported SPIVC with multi-use blood control septum (Introcan Safety® 3 B Braun 
Medical), compared with a ported SPIVC (Vasofix® Safety B Braun Medical).  In both arms 
of the study a vascular access device (VAD) was applied to the cannula (Smartsite®, Alaris).  
The study was part of an in service product evaluation within the trust. For the first arm of the 
study participants used the current ported safety SPIVC and separate components and used 
for the second arm, the cannulation packs with non-ported SPIVC with multi-use blood 
control septum were used. All cannulating staff was invited to participate in the study. 
 
2.2.2. Participants: Time in Motion 
All cannulating staff including junior doctors and nurses (Band 5 and 6) in Nottingham 
Queens Medical Centre Emergency Department were eligible for participation and received 
training on the non-ported SPIVC with multi-use blood control septum for a week prior to the 
commencement of the study. No data on the patient was collected, only clinician time was 
measured.  Permission from the Research and Development Centre of Nottingham University 
Hospitals NHS Trust was granted for this study. 
 
2.2.3. Data Collection: Time in Motion 
Three researchers collected the data overall. Prior to the study the researchers observed x 10 
simulated cannulations each and there were no differences in their recordings of the timings.  
Days for observation and which cannulations on those days to observe were randomised by 
coin toss. One researcher observed and collected data on cannulations on a specific day. This 
meant that the researcher could observe one procedure at a time; missing any other 
procedures taking place at the same time. The time taken was recorded with a stopwatch.    
 
2.2.4. Statistical Analysis: Time in Motion 
Sample size calculation for full time in motion study, comparing separate components with 
packs was based on estimation by clinical user of 300s per cannulation, a SD of 120s, a 
difference between means of 90s, power of 80% and alpha of 0.05. The estimated 300s per 
cannulation was confirmed with the observation of five cannulations prior to the study. This 
resulted in a sample size of 28 cannulations in each arm of the study. As this was based on 
timings from a small sample we aimed for a minimum of 50 samples per each study arm to be 
sure of effect. Statistical analysis was performed using a standard Student's t-test for 
continuous variables.    
 
2.3. Methods: Clinical Users' Perception  
Clinical users' perceptions phase of the study was preceded by a familiarisation stage – where 
data was collected by the research team and used to produce the sample size for the full 
study. Clinical users' perceptions of Introcan Safety® 3 were conducted in 14 NHS Trusts in 
the UK. The clinical users received training on Introcan Safety® 3 before the study 
commenced.  
 
The data from all of the evaluation forms (n=212) were explored: Previous type of cannula 
used (ported/non-ported), hospital trust, department, type of clinician, number of Introcan 
Safety® 3 inserted, was Introcan Safety® 3 easy to insert? Was Introcan Safety® 3 easy to 
penetrate the patient’s skin? Was first and second flashback easy to see? Is the cannula secure 
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when dressed?  Does the multi-use blood control septum prevent backflow of blood without 
digital vessel occlusion? Would you use Introcan Safety® 3 in clinical practice? 
 
The effect of previous cannula used, department and clinician type were investigated for 
effect on responses.  
 
2.3.1. Participants: Clinical Users' Perception  
Departments with high cannula use were identified for participation; Computerised 
Tomography and Magnetic Resonance Imaging departments (CT), Oncology, Surgical 
Wards, Emergency Departments (ED) and Medical Assessment Suite (MAS). All staff 
members working in those departments were invited to participate in the study. No incentives 
were offered to the participants. The data was collected between May 2012 and September 
2014.  
 
2.3.2. Sample Size Calculation: Clinical Users' Perception  
Sample size for the evaluation prior to clinical users' perceptions phase of the study was 
based on our wanting to demonstrate that greater than 80% (±5%) of clinicians would 
respond favourably to the non-ported SPIVC with multi-use blood control septum. This was 
based on a pre-familiarisation phase prior to the main study, which demonstrated an 
approximate 80% positive score. A sample size of 153 was required, in order to allow for a 
50% failure to complete forms, evaluations forms were sent to 306 participants in the second 
week of evaluation. In some instances the user did not answer all questions and resulted in a 
variable n value, for each question the per cent value is based solely on the participants who 
answered the questions.   
 
2.3.3. Statistical Analysis: Clinical Users' Perception  
Comparisons were made between different external factors and effect on the clinical user’s 
responses. External factors included; previous cannula use (ported versus non-ported), 
healthcare departments and type of clinical practitioners. Comparisons were performed using 
chi-squared test with post hoc comparison of residual values (Sharpe 2015). 
 
2.4. Cost Impact 
The key cost vectors identified to be directly impacted by the study were: (i) the cost of the 
cannula and (ii) the cost of the clinician time to complete the procedure.  Other costs that 
were viewed as constants (e.g. building costs) or not directly impacted by the introduction of 
a SPIVC with multi-use blood control septum were not included into cost analysis. 
 
The cost of the current cannula was calculated based on the average unit price of the two 
current main SPIVC used in the NHS based on the NHS Supply Chain catalogue price (the 
main supplier of medical equipment to NHS Trusts in the UK) in 2015 including VAT and 
delivery. Costs did not account for any increase over time and are calculated at the current 
level. Cost of clinician time to NHS Trust were calculated as per Figure 1 - These 
calculations produced an average hourly cost to a NHS Trust of £22.77 per hour, for 
clinicians who cannulate and for the purposes of calculations assume equal split amongst the 
different cannulators on different pay bandings and is a representation of average cost to NHS 
Trust for clinician time.   
 
For the overall cost offset, estimates of organisational level impact assumed that non-ported 
safety SPIVC with multi-use blood control septum could be introduced for 60% of NHS 
Trust cannula use, based on usage data in other NHS Trusts (unpublished B Braun sales data 
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2014), with the remaining 40% to be a ported SPIVC being used in areas such as theatres for 
rapid induction, resuscitation for immediate access via top port and also delivery 
departments. Cost effectiveness, calculated cost invested in SPIVC with multi-use blood 
control septum per hour clinician time saved. 
 
3. Results 
3.1.1. Main Findings: Time in Motion Study 
Twenty-nine clinicians took part in the study.  In arm one there were 14 clinicians and 15 in 
arm two.  There was an overlap of 5 clinicians whose cannulations were observed in both 
arms of the study. The time taken from skin cleansing through to completion of cannulation 
and documentation was an average of 185s (95% CI 154s – 216s) when clinicians were using 
the ported SPIVC (Table 1) and was reduced to an average of 131s (95% CI 114s-148s) when 
using the non-ported SPIVC with multi-use blood control septum.  The time to complete the 
final stage alone was reduced by an average of 54s (29%) (P≤0.005) by the introduction of 
the non-ported SPIVC with multi-use blood control septum.  
 
3.1.2. Estimated impact upon utilisation of staff time and cost offset 
Introduction of the SPIVC with multi-use blood control septum (for 60% of cannula) into a 
large NHS Trust of 1650 beds (such as the site used for this study) using 300,000 cannula, 
would result in releasing up to 2700 hours on nursing/junior doctor time p.a.  This assumes an 
approximate use of 185 cannula per bed; based on trust cannula volumes (unpublished B 
Braun sales data 2012/13) and bed number from 36 UK NHS Trusts websites (95% CI 177-
194).  Factoring in an hourly rate of £22.77 per hour (range £15.61 - £34.31) a large 1650 bed 
NHS Trust could release £61,479 of staff resource in efficiency improvement (range £42,147 
- £92,637). The above calculation looks only at the time efficiency saving but does not factor 
in the extra investment required for the introduction of a SPIVC with multi-use blood control 
septum. Introduction of a SPIVC with multi-use blood control septum, for 60% of the 
cannula in a trust of 1650 beds, would result in an average investment of £9,900 per annum 
(range £0.00 - £19,800) compared to the average cost of the two most commonly used  
SPIVC in NHS supply chain catalogue inc VAT. Factoring in the investment in a SPIVC with 
multi-use blood control septum, the average efficiency improvement could be of a 1650 bed 
trust could be £53,530 per annum (25% of current IVC spend) (range £22,374 - £92,637).  
These cost offset calculations look only at the direct costs associated with cannulation.  Other 
indirect and institution costs were not included into this calculation for simplicity and 
transparency.  Cost effectiveness calculations demonstrated an average investment of £3.67 
per hour of clinician time saved (range £0.00 - £7.33 per hour saved depending of current 
SPIVC used).  This is 84% less than the cost to NHS Trust for one hour of clinician time. 
 
3.2. Main Findings of the Clinical Users' Perception Study 
In total 212 forms were completed and figure 2 demonstrates the overall results from the 
clinical user perception study. Overall 70% of clinicians agreed or strongly agreed that the 
SPIVC with multi-use blood control septum was easy to use with minimum change in 
technique (n=147 out of 211). Eighty – four per cent (84%) of clinicians agreed or strongly 
agreed that the SPIVC with multi-use blood control septum penetrated the skin/vessel easily 
(n= 179 out of 212). Of the 8% of respondents who found it difficult to penetrate skin/vein 
(n=17 out of 212), 15 of these users had used the cannula infrequently (9 times or less) 
indicating a trend for increased ease of use with increased familiarity.  Eighty per cent (80%) 
of users agreed or strongly agreed that both flashbacks were seen easily (n=169 out of 212).  
The first flashback is the first back flow of blood into the flashback chamber of a cannula.  
The second flashback is seen in the catheter tip as the stylet is withdrawn and catheter 
7 
 
advanced. Flashbacks are used to determine successful puncture and advancement of catheter 
into the vein. Similarly; eighty per cent (80%) of users agreed or strongly agreed that cannula 
was secure when dressed (n=168 out of 211). Eighty–seven per cent (87%) of clinicians 
(n=184 out of 210) agreed or strongly agreed that the multi-use blood control septum 
prevented the back flow of blood, with only 5% users commenting that back flow of blood 
was still present (n= 11 out of 210). Of these, two users removed the stylet very slowly 
(>15s) keeping the septum open and on one occasion the clinician removed the hydrophobic 
stopper from flashback chamber so saw “leaking” outside of the remit of the septum. 
 
Evaluation forms were collected from five types of clinical areas: Computerised Tomography 
and Magnetic Resonance Imaging departments (CT) (40.6%), Oncology (23.1%), Surgical 
Wards (15.1%), Emergency Department (ED) (12.7%) and Medical Assessment Suite (MAS) 
(A step down unit from emergency departments in the UK) (8.5%).  The responses from the 
MAS were different to all other areas for 5 of the 6 questions asked (Figure 3). More clinical 
users from the MAS strongly disagreed that SPIVC with multi-use blood control septum was 
easy to use with minimum change in technique (16.7% n=3 out of 18) (P<0.05) compared to 
other clinical departments (0% - 6.25%).  More clinical users from the MAS strongly 
disagreed that the first and second flashbacks were easy to see (16.7% n=3 out of 18) 
(P<0.05) compared to other clinical departments (0% - 3.13%).  In addition, more clinical 
users from MAS disagreed that the SPIVC with multi-use blood control septum penetrated 
the skin/vessel easily (27.8% n=5 out of 18) (P<0.05) compared to other clinical departments 
(2% - 11%).  When asked if the cannula was secured when dressed, more clinicians from 
MAS strongly disagreed (16.7% n=3 out of 18) (P<0.05) compared with other clinical areas 
(0% - 6.1%).  When asked if the blood control septum prevented the back flow of blood, 
more clinicians from MAS disagreed (16.7% n=3 out of 18) and neither agreed nor disagreed 
(27.8% n=5 out 18) (P<0.05) compared with other areas (0% - 6.1% and 2% - 3.7% 
respectively).  The results from MAS accounted for only 8.5% of the evaluations completed 
(n = 18), this small number may have skewed the data when comparing effect of department.  
However overall in response to “would you use Introcan Safety® 3 in clinical practice”, the 
majority of clinicians in the MAS responded with “yes” (72.2 % n=13 out of 18) and was in 
line with other departments (77.2% - 92.9%).  Another difference between the departments 
was noted in the Emergency Departments, here more clinicians strongly agreed that “that 
Introcan Safety® 3 was easy to use” (55.6% n=15 out of 27) (P<0.05) (Figure 4). 
 
Various clinicians completed evaluation forms: radiographers (39.6%), nurses (34.9%), 
doctors (21.7%), and healthcare assistants (HCA’s) (3.8%) (Who cannulate in some trusts).  
More of the HCA’s strongly agreed that the SPIVC with multi-use blood control septum 
penetrated the skin/vessel easily (87.5% n=7 out of 8) (P<0.05) compared with other 
clinicians (38.1% - 41.3%). More HCA’s strongly agreed that the SPIVC with multi-use 
blood control septum was secure when dressed (100% n=8 out of 8) (P<0.05) compared with 
other clinicians (28.3% - 37.3%). There were only 8 responses by HCA’s (3.8%), which may 
have skewed the data from this subset when comparing to other clinicians. More medics 
strongly disagreed that the first and second flashbacks were easy to see in the SPIVC with 
multi-use blood control septum (6.5% n=3 out of 46) (p<0.05) compared to other clinicians 
(0% - 1.2%).  However, overall there was no difference between the clinicians when asked, 
“Would you use this device in clinical practice” with all groups falling in the range 77.5%-
88.9%. 
 
Overall 82% (n=174 out of 212) of clinicians would use the SPIVC with multi-use blood 
control septum in clinical practice (Figure 4). Ten per cent (10%) of clinical users (n=22 out 
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of 212) would not choose to use SPIVC with multi-use blood control septum in clinical 
practice.  Of the 22 users who would not use the non-ported SPIVC with multi-use blood 
control septum, 21 had previously exclusively used a ported cannula, indicating more concern 
when moving from a ported to non-ported SPIVC.  Twelve users commented on difficulty in 
changing technique with a non-ported cannula, 7 clinicians did not comment as to why they 
would not use, 3 found it more difficult to dress the cannula and 7 did not see the flashback 
clearly.   
 
Sixty - nine per cent (69%) of users agreed or strongly agreed that there was a minimal 
change in technique (n=147 out of 212).  Clinicians familiar with a ported cannula found that 
there was a larger change in technique (22.7%, n=35 out of 154) compared to users familiar 
with non-ported cannula (6.9%, n=4 out of 58).   Indeed, significantly more clinicians who 
were previously using a non-ported cannula, strongly agreed that the SPIVC with multi-use 
blood control septum was easy to use with minimal change in technique (46.5%, n=27 out of 
58) compared to previous ported cannula users (25.3% n=39 out of 154) (P<0.05). In addition 
fewer clinicians, previously using a non-ported cannula, responded that they would not 
choose to use the SPIVC with multi-use blood control septum (P<0.05) (1.7%, n=1 out of 58) 
compared to previous ported cannula users (14.3% n=22 out of 154). 
 
4. Discussion 
Since its launch in 1948, the NHS has grown to become the world’s largest publicly funded 
health service. The NHS deals with over 1 million patients every 36 hours and in a recent 
survey found that there was 60 per cent more operations completed by the NHS in 2012/13 
compared to 2002/03, with an increase from 6.6million to 10.6million.  The total annual 
attendance at Emergency Departments was 32 per cent higher than a decade earlier (NHS 
Confederation).  The NHS is likely to face further pressures as the UK population is 
estimated to increase from an estimated 63.7 million 2012 to 71.04 million by 2030.  
Furthermore, the number of people aged 65 and over is projected to increase from 10.84m in 
2012 to 17.79m by 2037. As part of this growth, the number of over-85’s is estimated to more 
than double from 1.44 million in 2012 to 3.64 million by 2037 (NHS Confederation). With 
the increasing numbers of patients requiring the NHS services it is imperative that clinicians 
are able to work in the most efficient means possible.  With one third of all patients in the UK 
admitted to the NHS receiving at least one PIVC (Boyd 2011)
 
this is an area of time 
consumption to the NHS staff.   
 
This study has demonstrated in one A&E department an average time saving of 54s (29%) 
per cannulation when using a novel non-ported SPIVC with multiple use blood control 
septum when compared to a ported SPIVC.  The presence of a blood control septum removes 
the requirement for a clinician to occlude the vein, hence freeing up a second hand to secure 
the SPIVC while; the stylet is removed, VAD is attached and dressing applied which may 
well account for the time saving observed.  Previously, Haeseler at al 2014, using the same 
non-ported SPIVC with multi-use blood control septum, in a study of 200 cannulations in a 
pre-operative setting, reported a time saving of 10s from venepuncture to attachment of VAD 
and a time saving of 15s from venepuncture to fully dressed cannula.  Further more Haesler 
et al (2014), observed that vein occlusion was required in 2% of cannulations with the non-
ported SPIVC with multi-use blood control septum compared with 96% of cannulations with 
a standard SPIVC without blood control septum. Also 80% of the clinicians that did not 
compress the vein stated that omission of vein compression improved the procedure of 
cannulation since both hands could be used during removal of the needle and catheter 
connection. It is interesting that in the controlled environment of the pre-operative setting that 
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a time saving was also found, albeit less than observed here, and this may be due to the 
differences in patients and conditions in the differing areas.  It is difficult to directly compare 
these two studies as different stage markers were used for timings and the two study areas are 
very different.  It is likely that the greater time saving observed here in the A&E department 
may be due to greater variation in patient compliance and ease of venous access.  Indeed it 
was commented by the users on 7 occasions that the venous access was difficult.  Of these 7 
“difficult to cannulate” patients, five occurred during the use of the standard ported safety 
SPIVC section of the trial and two occurred while the non-ported safety SPIVC with multi-
use blood control septum was being timed.  Even though the users commented on these 
patients being difficult, all except one was inside the normal variation of cannulation times 
across the two groups.   
 
There is a risk of potential infection to healthcare workers with each application of any PIVC 
as the clinician is exposed to patient’s blood.  The risk of accidental needlestick injury could 
be near eliminated by the introduction of a safety cannula (Asai et al 1999, Prunet et al 2008) 
and in light of this view the EU Council Sharps Directive 2010/31/EU came in to action in 
April 2013 recommending the use of sharp safe products in the healthcare setting.  Haeseler 
et al 2014, observed that the septum prevented backflow of blood in 95.1% of cannulations 
from the non-ported SPIVC with blood control septum, whereas use of a SPIVC without 
septum, using standard occlusion techniques, only prevented back flow in 32.5% of 
cannulations.  They also observed that upon manipulation of the IV cannula (for catheter 
connection and disconnection procedures such as blood sampling or change of infusion line) 
there was no blood leakage with the non-ported SPIVC with multi-use blood control septum 
compared to 74% of manipulations with the non-ported SPIVC without septum. In addition 
Seiberlich et al 2015 (using a different SPIVC with septum to prevent back flow of blood for 
initial venepuncture) found than digital compression was not required to prevent back flow of 
blood when a non-ported SPIVC with a blood control septum was used (95.5%), compared to 
using a non-ported SPIVC without septum (19.1%). Prevention of exposure to blood may 
protect healthcare workers from exposure to potential blood borne pathogens and supports 
best practise for healthcare workers (Health and Safety at work Act 1974, Jagger et al 2011, 
Shillie et al 2013).  While this study was not directly designed to measure success rate of the 
multi-use septum, only 5% (n= 11 out of 214) of users in the clinical evaluation commented 
that there was still back flow of blood.  Anecdotally, clinicians during the evaluation did 
comment positively on there being “less mess with these new cannulas”, further 
demonstrating that there is a perceived benefit of the multiple use blood control septum to the 
clinician.  The clinical evaluation here was not designed as a full in-depth qualitative study.  
In light of the anecdotal comments received it would be of interest to obtain a full qualitative 
report of the healthcare workers perception of the multi-use blood control septum and how 
this impacts their practice. 
 
Here we further looked at the cost offset of introducing Introcan Safety 3 into NHS Trusts in 
the UK by factoring in additional cost of the SPIVC with multi-use blood control septum 
compared to the time saved as a cost of clinician time to the trust. Healthcare workers time 
accounts for 40% of the NHS annual expenditure (General Election 2010). Ensuring 
healthcare workers time is utilised to the best it can be has been the focus of government 
initiatives such as The Productive Series.  This initiative set out by the Institute of Innovation 
and Improvement supports NHS teams to redesign and streamline the way they manage and 
work. The aim is to achieve significant and lasting improvements, predominately in the extra 
time that they give to patients, as well as improving the quality of care delivered whilst 
10 
 
reducing costs. The study results reported in this paper are from a one site study in one 
department and need to be interpreted with caution.  
 
There is also a nature of human error possible in the recording of the timings on the data as 
three different observers were used. Prior to the study the three observers simultaneously 
observed 10 practice scenarios set up in a lab using a training arm and different cannulators – 
under these circumstances there was SD of 0.45 seconds between the timings measured by 
the three observers demonstrating minimal error, however a lab set up is different from the 
real scenario in a busy Emergency Department and a level of error could be expected.  
 
It was impossible to blind the timing observers. Clinicians were aware they were being timed 
and that may have impacted on the timings of the study.  Indeed the observers commented 
that some staff did become very enthusiastic to “beat the clock” initially when using the 
current cannulation equipment.  However, it was also noted that this enthusiasm waned as the 
study went on; despite this a time saving was demonstrated by using the SPIVC with multi-
use septum. 
 
A larger study across multiple sites and multiple departments would provide further evidence 
on the potential impact of clinician time saving that might be made. 
With this introduction of the European Union safety directive on sharps (European 
Commission Directive 2010), the Health and Safety Executive issued a guide for the NHS 
employers and employees to assist in the compliance.  This guide recommending that end 
users were engaged in the selection process of any sharp safe devices to be introduced into an 
NHS Trust (HSE 2013). This study also investigated the clinical user perception of a new 
SPIVC with multi-use blood control septum and found that the majority of end users, from a 
range of institutions and clinical backgrounds, found the device would be chosen for clinical 
use by the majority of clinical users. Clinical acceptability studies are rare, however other 
blood control SPIVC’s have also been demonstrated to be clinically accepted in single centre 
studies in America (Seiberlich et al 2015, Onia et al 2011), and these studies also 
demonstrated the reduced need for digital compression to prevent back flow of blood.  These 
two studies, based in America, compare a like for like cannula with the new version 
containing a blood control septum. In America it is standard practice for a non-ported cannula 
to be used, which is not as common a practice in the UK.  In this current study the evaluators 
were a mix of current ported cannula users (75%) and non-ported cannula users (25%).  
Noticeably only 1.7% of the current non-ported cannula users would not use the SPIVC with 
blood control septum, in agreement with the observations in America.  However for the 
majority of users, who had to change cannulating technique to use a non-ported cannula, 
there was an increase to 14.3% of clinicians choosing not to use.  The clinical user perception 
study took place for two weeks, having 86% of users choosing to use or neutral to using the 
new SPIVC even with a change in technique is of interest in the UK where infection control 
teams are looking to introduce closed systems due to high contamination rates of top ports 
(Oberhammer 1979). 
 
5. Summary and Conclusions 
The study indicates that introduction of a non-ported SPIVC with multi-use-blood control 
septum could be well received, with the appropriate level of training of healthcare staff.  The 
study has revealed a time saving of ~29% per cannulation (54s), compared to standard 
11 
 
cannulation practices. This may suggest that introduction of non-ported SPIVC with multi-
use blood control septum may provide efficiency savings across a trust; however this will 
vary depending on current practices within each hospital and also with differing practices 
within different areas of the trust.   
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Nurses band 5/6 and Doctors F1-
SHO do most cannulations 
Saturdays = +30%*** 
Assuming 2 weekends out of 4. 
= 23.5 Saturdays per year =282 hrs  @+30% 
 
Sundays = + 60%*** 
Assuming 2 weekends out of 4. 
= 23.5 Sundays per year =282 hrs @+ 60% 
282hrs x(£9.53) = +£2687.48 per year 
Unsocial working =  +(705 hr @+30%) 
+ (282 hrs @+60%) 
+basic hourly cost to trust 
Hourly cost to NHS Trust 
Applying pay bandings 1a, 2a and 2b salary 
and average§§ 
 
  
 
Contracted for 40 hours and 5 weeks holiday 
= 47 weeks work/year§§ 
(Salary+Pay banding/47)/40 hours 
=  cost to trust per hour 
Average of all hourly rates  - cost to NHS Trust 
Nights = +30%*** 
Assuming 1wk/4 = nights  and3x12hr shifts 
per wk of nights = 36hrs per wk nights). 
47 wks/4 =11.75wks nights / year. 
36 hours x 11.75 weeks  = 423 hrs + 30% 
Band5/6 nurse salary* Doctors HO/SHO salary§ 
Contract 37.5 hrs/wk and average 5 weeks 
holiday = 47 wks per year working** 
(Salary/47)37.5 
= basic cost to trust per hour 
*Salary for Nurses (NHS Careers 2013).                                                                                                            
**Based on 37.5 hour week and average holidays of 37 days per year (Pay scale).                                                       
***Unsociable working appropriate for pay band 5 and 6 (NHS Careers 2013).                                                   
§Junior Doctors salary (NHS Employers 2013) .                                                                                            
§§Additional pay bandings (Department of Health Social Services and Public Safety 2000), (British Medical 
Association).   
Figure 1 – Flow chart for calculations of cost of clinician time as a cost to NHS Trust. 
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Time (seconds) 
  
n 
 
Mean 
 
SD 
 
95% CI 
 
Min 
 
Median 
 
Max 
 
Overall 
 
103 
 
158 
 
95 
 
140-176 
 
14 
 
136 
 
642 
 
Vasofix® 
Safety 
 
51 
 
185 
 
114 
 
154-216 
 
30 
 
167 
 
 
642 
 
Introcan 
Safety® 
 
52 
 
131 
 
62 
 
114-148 
 
14 
 
130 
 
300 
 
P Value 
 
P<0.005 
 
Table 1. The table illustrates time (in seconds) taken from skin cleansing to completion of 
cannulation, with attachment of the vascular access device (VAD) and completion of paperwork for 
the two different cannula systems, the same VAD and documentation was used in both arms of study. 
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Figure 2. Overall results from Introcan Safety® 3 UK wide evaluation, results from n=212 clinicians.   
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Figure 3 Clinical User Perception Responses – represented by clinical department (ED = 
Emergency Department, CT = Computerised Tomography and Magnetic Resonance Imaging, 
Chemo = chemotherapy, MAS = Medical Assessment Suite). 
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Figure 4 Per cent responses to “would you use Introcan Safety® 3 in clinical practice?”.  
Answers expressed as overall, department and by previous cannula use. (CT = Computerised 
Tomography and Magnetic Resonance Imaging, ED = Emergency Department, MAS = 
Medical Assessment Suite). 
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Figure 5 Clinical User Perception Responses – represented by clinician type. 
 
 
 
